Pharmacotherapy of anxiety disorders: A critical review

Dialogues in Clinical Neuroscience

Volumn 13, Issue 4, 2011, Pages 423-437

  Koen, Nastassja ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anxiety disorder; Generalized anxiety disorder; Medication; Obsessive compulsive disorder; Pharmacotherapy; Post traumatic stress disorder; Social anxiety disorder

Indexed keywords

AGOMELATINE; ALPRAZOLAM; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CYCLOSERINE; DESIPRAMINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LORAZEPAM; MEMANTINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; ONDANSETRON; PAROXETINE; PREGABALIN; QUETIAPINE; REBOXETINE; RILUZOLE; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE; ANXIOLYTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ARTICLE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSIVE CRISIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT COMPLIANCE; PLASMAPHERESIS; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRESYNAPTIC MEMBRANE; PSYCHOBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SOCIAL ADAPTATION; SOCIAL PHOBIA; TRANQUILIZING ACTIVITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANXIETY DISORDER; EVIDENCE BASED MEDICINE; REVIEW;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84857666179     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291:2581-2590.
2. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010;2:21-35.
3. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalised anxiety disorder. Int J Neuropsychopharmacol/ Official Scientific Journal Of The Collegium Internationale Neuropsychopharmacologicum (CINP). 2005;8:293-302.
4. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;CD003592.
5. Baldwin D, Buis C, Mayers A. Selective serotonin reuptake inhibitors in the treatment of generalised anxiety disorder. Exp Rev Neurotherapeutics. 2002;2:717-724.
6. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol: Clin Exp. 2010;25:17-29.
7. Baldwin D, Woods R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;324:1-11.
8. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association of Psychopharmacology. J Psychopharmacol. 2005;19:567-596.
9. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9:248-312.
10. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on generalised anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62(suppl 11):53-58.
11. Swinson RP, Antony MM, Bleau PB, et al. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry. 2006;51(suppl 2):1-92.
12. Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav. 2011;99:217-228.
13. Steckler T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr Top Behav Neurosci. 2010;2:415-428.
14. Spooren W, Lesage A, Lavreysen H, Gasparini F, Steckler T. Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci. 2010;2:391-413.
15. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71:839-854.
16. Rynn MA, Brawman-Mintzer O. Generalised anxiety disorder: acute and chronic treatment. CNS Spectrums. 2004;9:716-723.
17. Rynn M, Russel J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalised anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25:182-189.
18. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebocontrolled trial. Psychol Med. 2009;39:267-276.
19. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a doubleblind, placebo-controlled trial. Eur Neuropyschopharmacol. 2008;18:673-681.
20. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology. 2005;177:448-458.
21. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24:479-499.
22. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalised anxiety disorder: a randomised, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561-566.
23. Stein D, Ahokas A, Allgulander C, et al. P01-181 - Long-term treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months. Eur Psychiatry. 2011;26(suppl 1):181.
24. Martin JLR, Sainz-Pardo M, Furukawa TA, et al. Review: benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21:774-782.
25. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalised anxiety disorder. J Psychopharmacol. 2007;21:864-872.
26. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalised anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49:293-301.
27. Chessick CA, Allen MH, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006115.
28. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368:2156-2166.
29. Coplan JD, Tiffon L, Gorman JM. Therapeutic strategies for the patient with treatment-resistant anxiety. J Clin Psychiatry. 1993;54(suppl):69-74.
30. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsyschiatr Dis Treat. 2007;3:185-191.
31. Montgomery S, Chatmara K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br JPsychiatry. 2008;193:389-394.
32. LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second-generation anti-psychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011;31:326-333.
33. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;12:CD008120.
34. Katzman MA, Vermani L, Jacobs M, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22:1480-1486.
35. Pollack MH, Otto MW, Roy-Byrne PP, et al. Novel treatment approaches for refractory anxiety disorders. Focus. 2008;6:486-495.
36. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24:269-275.
37. National Institute for Clinical Excellence (NICE). The Management of Panic Disorder and Generalised Anxiety Disorder in Primary and Secondary Care. London, UK: National Collaborating Centre for Mental Health; 2004.
38. Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol. 2011;26:63-68.
39. Kuzma JM, Black DW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr Psychiatry Rep. 2004;6:268-273.
40. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359:2753-2766.
41. Kodish I, Rockhill C, Ryan S, Varley C. Pharmacotherapy for anxiety disorders in children and adolescents. Pediatr Clin N Am. 2011;58:55-72.
42. Goodwin RM, Gorman JM. Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am J Psychiatry. 2002;159:1935-1937.
43. Davis M, Myers KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52:998-1007.
44. Madaan V, Wilson DR. Neuropeptides: relevance in treatment of depression and anxiety disorder. Drug News Perspect. 2009;22:319-325.
45. Uys JD, Stein DJ, Daniels WM. Neuroproteomics: relevance to anxiety disorders. Curr Psychiatry Rep. 2006;8:286-290.
46. Uys JD, Hattingh SM, Stein DJ, Daniels WM. Large scale hippocampal cellular distress may explain the behavioral consequences of repetitive traumatic experiences--a proteomic approach. Neurochem Res. 2008;33:1724-1734.
47. Zohar J, Insel TR, Zohar-Kadouch RC. Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988;45:167-172.
48. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;23:CD001765.
49. Denys D, Zohar J, Westenberg HGM. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65:11-17.
50. Joel D, Stein J, Schreiber R. Animal models of obsessive-compulsive disorder: from bench to bedside via endophenotypes and biomarkers. In: Robert AM, Franco B, eds. Animal and Translational Models for CNS Drug Discovery. San Diego, CA: Academic Press; 2008:33-164.
51. Korff S, Stein DJ, Harvey BH. Stereotypic behaviour in the deer mouse: Pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:348-355.
52. Geller DA, Biederman J, Stewart SE, et al. Review: clomipramine is more effective than SSRIs for paediatric obsessive compulsive disorder. Evid Based Mental Health. 2004;7:50.
53. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipraine: a placebocontrolled study. Arch Gen Psychiatry. 1998;55:918-924.
54. Schruers K, Koning K, Luermans J, Haack MJ, Hriez E. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand. 2005;111:261-271.
55. Vythilingum B, Cartwright C, Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 2000;15(suppl 2):7-13.
56. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. American Psychiatric Association. Practice guideline for the treatment of obsessive compulsive disorder. Am J Psychiatry. 2007;164(suppl 7):5-53.
57. Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessivecompulsive disorder. CNS Spectr. 2007;12(suppl 3):28-35.
58. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessivecompulsive disorder. Int J Neuropsychopharmacol. 2005;8:107-129.
59. Zohar J, Hollander E, Stein DJ, Westenberg HG. Consensus statement. CNS Spectr. 2007;12(2 suppl 3):59-63.
60. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15:850-855.
61. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int Clin Psychopharmacol. 2002;5:181-191.
62. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol. 1997;17:4-10.
63. Bloch MH, Landeros-Weisenberger A, Kelmedi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatmentrefractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622-632.
64. McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind placebocontrolled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.
65. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. Focus. 2007;5:354-360.
66. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;CD005473.
67. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessivecompulsive disorder. J Clin Psychiatry. 2011;72:216-221.
68. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics. 2006;3:69-81.
69. Coric V, Krystal JH, Sanacora G. Glutamate agents in the treatment of mental disorders. Experimental NeuroTherapeutics. 2006;3:69-81.
70. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessivecompulsive disorder. J Clin Psychopharmacol. 2010;30:34-39.
71. Deveney CM, McHugh RK, Tolin DF, Pollack MH, Otto MW. Combining D-cycloserine and exposure-based CBT for the anxiety disorders. Clin Neuropsychiatry. 2009;6:75-82.
72. Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol Clin Exp. 2010;25:509-513.
73. Leonard HL, Swedo SE. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). Int J Neuropsychopharmacol. 2001;4:191-198.
74. Martino D, Defazio G, Giovannoni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosomat Res. 2009;67:547-557.
75. Cortese I, Chaudhry V, So Y, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294-300.
76. Royal College of Psychiatrists. Neurosurgery for mental disorder. Report from the Neurosurgery Working Group of the Royal College of Psychiatrists. 2000;Council Report CR89.
77. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52:1263-1274.
78. Greenberg BD, Malone DA, Friehs GM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31:2384-2393.
79. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia. 1964;5:397-408.
80. Stein MB, Goin MK, Pollack MH. Practice Guidelines for the Treatment of Patients with Panic Disorder. 2nd ed. Washington (DC): American Psychiatric Association (APA). Work Group on Panic Disorder; 2010.
81. Bakker A, van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol. 2005;8:473-482.
82. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy of and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158:1989-1992.
83. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106:163-167.
84. Noyes R, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. J Clin Psychiatry. 1989;50:163-169.
85. Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW. Pharmacologic treatment of panic disorder. Curr Top Behav Neurosci. 2010;2:469-485.
86. Seedat S, van Rheede VO, Muller JE, Mohr N, Stein DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003;18:279-284.
87. Seretti A, Chiesa A, Calari R, Perna G, Bellodi L, De Ronchi D. Novel antidepressants and panic disorder: evidence beyond current guidelines. Neuropsychobiology. 2011;63:1-7.
88. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gapabentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
89. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145:1104-1109.
90. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998;43:73-77.
91. Woodman CL, Noyes R. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134-136.
92. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:556-559.
93. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000;10:165-169.
94. Dannon PN, Hirschmann S, Kindler S, Iancu T, Dolberg OT, Grunhaus LJ. Pindolol augmentation in the treatment of resistant panic disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 1997;7(suppl 2):231.
95. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006;188:305-312.
96. Mathew SJ, Coplan JD, Gorman JM. Management of treatment-refractory panic disorder. Psychopharmacol Bull. 2001;35:97-110.
97. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioural therapy and medication for primary panic disorder. Arch Gen Psychiatry. 2005;62:290-298.
98. Heldt E, Manfro GG, Kipper L, et al. Treating medication-resistant panic disorder: predictors of outcome of cognitive-behaviour therapy in a Brazilian public hospital. Psychother Psychosom. 2003;72:43-48.
99. Heldt E, Gus MG, Kipper L, Blaya C, Isolan L, Otto MW. One-year follow-up of pharmacotherapy-resistant patients treated with cognitive-behaviour therapy: outcome and predictors of remission. Behav Res Ther. 2006;44:657-665.
100. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behaviour therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994;55:200-205.
101. Lopes VL, Sebastiao AM, Ribeiro AJ. Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Topics Medicin Chem. 2011;11:1087-1101.
102. Stein DJ, Ipser JC, McAnda N. Pharmacotherapy of post-traumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 2009;14(1 suppl 1):25-31.
103. Davidson JRT, Stein DJ, Shalev AY, Yehuda R. Posttraumatic stress disorder: acquisition, recognition, course, and treatment. J Neuropsychiatry Clin Neurosci. 2004;16:135-147.
104. Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: possible treatment of PTSD. J Clin Psychiatry. 1985;46:385-388.
105. Davidson JR, Kudler HS, Saunders WB, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993;150:1024-1029.
106. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch for the practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Psychiatric Association; 2009.
107. National Institute for Clinical Excellence (NICE). Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline number 26. London, UK: The Royal College of Psychiatrists and the British Psychological Society; 2005.
108. Stein DJ, Cloitre M, Nemeroff CB, et al. Cape Town consensus on posttraumatic stress disorder. CNS Spectr. 2009;41(suppl 1):52-58.
109. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000;61(suppl 5):60-66.
110. Davidson JR, Waker JI, Kilts C. A pilot study of phenelzine in the treatment of post-traumatic stress disorder. Br J Psychiatry. 1987;150:252-255.
111. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guidelines series: treatment of posttraumatic stress disorder. J Clin Psychiatry. 1999;60(suppl 16):1-76.
112. Stein DJ, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 2003;8:31-39.
113. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226-1229.
114. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:201-206.
115. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebocontrolled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27:677-681.
116. Seedat S, Lockhat R, Kaminer D, Zungu-Dirwayi N, Stein DJ. An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol. 2001;16:21-25.
117. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003;23:193-196.
118. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18:1-8.
119. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2002;159:1777-1779.
120. Pitman RK, Sanders KM, Zusmana RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002;51:189-192.
121. Brunet A, Orr SP, Tremblaya J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42:503-506.
122. Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhausler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry. 2001;50:978-985.
123. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry. 2004;55:627-633.
124. McGhee LL, Maani CV, Garza TH, et al. The effect of propranolol on post-traumatic stress disorder in burned service members. J Burn Care Res. 2009;30:92-97.
125. Muravieva EV, Alberini CM. Limited efficacy of propranolol on the reconsolidation of fear memories. Learn Mem. 2010;17:306-313.
126. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of Dcycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol. 2005;5:301-307.
127. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60:369-375.
128. Norberg MM, Krystal JH, Tolina DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63:1118-1126.
129. Van Ameringen M, Mancini C, Pipe B, Bennet M. Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr. 2004;9:753-762.
130. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004;4:CD001206.
131. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry. 1991;48:938-945.
132. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry. 1992;49:290-300.
133. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67:286-295.
134. Davidson JRT. Pharmacotherapy of social phobia. Acta Pscyhiatrica Scandinavica. 2003;108(suppl 417):65-71.
135. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010;12:471-477.
136. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
137. Connor KM, Davidson JR, Potts NI, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998;18:373-378.
138. Van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin re-uptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomised control trials. Int Clin Psychopharmacol. 2000;15(suppl 2):S15-S23.
139. Blanco C, Raza MS, Schneier F, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6:427-442.
140. Mula N, Pini S, Cassano G. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol. 2007;27:263-272.
141. Jefferson JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry. 2001;62(suppl 1):50-53.
142. Ganasen KA, Stein DJ. Pharmacotherapy of social anxiety disorder. Curr Top Behav Neurosci. 2010;2:487-503.
143. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin-reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999;14:239-245.
144. Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry. 2003;57:313-315.
145. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;8:115-121.
146. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65:244-248.
147. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23-30.
148. Hoffman SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther. 2007;45:1987-2001.
149. Ganasen KA, Ipser JC, Stein DJ. Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin North Am. 2010;33:687-699.
150. Lochner C, Hemmings S, Seedat S, et al. Genetics and personality traits in patients with social anxiety disorder: a case-control study in South Africa. Eur Neuropsychopharmacol. 2007;17:321-327.
151. Warwick JM, Carey P, van der Linden G, et al. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis. 2006.
152. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428-1434.
153. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009:CD005170.
154. Lenze EJ, Rollman BL, Shear K, et al. Escitalopram for older adults with generalised anxiety disorder. JAMA. 2009;301:295-303.
155. Garner M, Mohler H, Stein DJ, Mueggler T, Baldwin DS. Research in anxiety disorders: from the bench to the bedside. Eur Neuropsychopharmacol. 2009;19:381-390.
156. Seedat S, Warwick J, van Heerden B, et al. Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord. 2003;80:45-53.
157. van Heerden JH, Conesa A, Stein DJ, et al. Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse. BMC Research Notes. 2009;2:195.
158. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalised anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749-756.
159. Stocchi F, Nordera G, Jokinen RH, et al. Paroxetine Generalised Anixety Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalised anxiety disorder. J Clin Psychiatry. 2003;64:347-351.
160. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalised anxiety disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry. 2001;62:350-357.
161. Davidson JRT, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo-controlled, flexible-dose study. Depress Anxiety. 2004;19:234-240.
162. Eddy KT, Dutra L, Bradley R, Western D. A multidimentional metaanalysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychology Rev. 2004;24:1011-1030.
163. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317.
164. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.
165. Greist JH, Jefferson JW, Kobak KA. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry. 1995;52:53-60.
166. Stein DJ, Spadaccini E, Hillander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:11-18.
167. Marshall RD, Neene KL, Oldman M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158:1982-1988.
168. Tucker P, Zaninelli R, Yehudy R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:860-868.
169. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283:1837-1844.
170. Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58:485-492.
171. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006;26:259-267.
172. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63:1158-1165.
173. Federoff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2000;21:311-324.
174. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18:29-40.
175. Hedges DW, Brown BL, Shwalb DA, et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol. 2007;21:102-111.